Skip to main content

Table 3 The patient demographical, and laboratory outcomes during the hospital stay

From: Management skin manifestation of multisystem inflammatory syndrome associated with SARS-CoV-2

Age (yrs), sex, race/ethnicity, location, BMI. Underlying medical conditions Clinical signs and symptoms Previous respiratory illness/SARS-CoV-2 testing SARS-CoV-2 testing at time of MIS-A admission Imaging/Other diagnostic studies Treatments Outcome and length of stay Screened microorganisms Laboratory findings
43-year old, male, caucasian , BMI:26 kg/m2 None Fever, weakness, joint pain, abdominal pain, headache, redness eyes, skin lesions Self isolation between Apr 13-24, 2021, COVID 19 PCR (-) on Apr 13, 2021 PCR (-) on Jun 7-9, 2021; Antibody test (+) on Jun 10 2021 Thorax CT: Normal; Abdominal CT:Normal; Abdominal ultrasonography: grade 1 hepatosteatos; at initial admission:[ECHO EF:60, ECG; negative T and non-specific ST-T segmental changes (V1-V6 )]At the discharge [ECHO: EF 64% and normal ECG.] Steroid, IVIG, and LMWH Disovered completely, and discharged at 14th of the treatment Multiple blood cultures N C-reactive protein( < 5 mg/L) 144*
         Urine culture N D-dimers ( < 500 µg/L) 2033*
         Rectal swab for multi-drug resistant bacteria N Ferritin (30-400 µg/L) 3978*
         HBV and HCV N Lactate dehydrogenase (135-225 U/L) 589*
         Leptospira N White blood count (4.5-10.5x10^9/L) 11.7*
         Borrelia burgdorferi N Neutrophil count ( 45-78 %) 85.5*
         SARS-CoV-2 (PCR) N Lymphocyte count (1.32-3.57x10^9/L) 0.74**
         SARS-CoV-2 (Antibody test) P Platelet count (150–400x10^9/L) 78**
         CMV IgG P Creatinine (07-1.2mg/dl) 0.9*
         CMV IgM N Troponin T(0.004 µg/L<) 0.005*
         EBV IgG N prokalsitonin(< 0.5 µg/L) 2.35*
         EBV IgM N AST(<40 U/L) 404*
         Weil felix test N ALT(<41 U/L) 874*
         HIV N T.Bilirubine(1.2mg/dl<) 2.06*
         Rickettsia conorii N Sedimantation(mm) 61*
         HAV TOTAL P Amilaz(28-100 U/L) 60*
         HAV IgM N Lipaz(13-60 U/L) 55*
         Brucella N Protrombin time (11"-16.8") 16.4*
         TPHA N   
         VDRL-RPR N   
  1. Screen microorganisms were checked from the patient urine, blood and rectal swab during his stay at the infectious department. Throughout his hospital stay, determined his maximum (*) and minimum (**) laboratory findings were shown
  2. BMI Body mass index, P Positive, N Negative, IVIG Intravenous immune globulin, LMWH Low molecular weight heparin, * = Maximum value at the given range; ** = Minimum value at the given range